◎StiefelがWelichenからWBI-1001の独占権取得
◎StiefelがWelichenからWBI-1001の独占権取得
AsiaNet 49507
共同JBN0729（2012.5.31）
◎StiefelがWelichenからWBI-1001の独占権取得
【リサーチトライアングルパーク（米ノースカロライナ州）2012年5月31日PRN＝共同JBN】GSK（NYSE:GSK）グループの1企業であるStiefel（スティーフェル）とWelichem Biotech,Inc.（WBI:CN）は中国、台湾、マカオ、香港を除くすべての地域で新しい抗炎症剤WBI-1001の独占的な開発権、商業化権をStiefelが取得する契約を結んだ。WBI-1001は乾癬、アトピー性皮膚炎の治療薬として現在、第II相臨床開発段階にある。この取引はWelichem株主の承認が必要である。
Welichemは3500万カナダドル（CAD）の当初支払いを受け取り、一定の臨床開発マイルストーンの達成時点、一定の国で対応する規制当局の販売認可を受けた商業化時点で追加的なマイルストーン支払いを受ける。
契約条件に従ってStiefelは中国、台湾、マカオ、香港全体でWBI-1001を開発、商業化する独占権を取得する条件付き権利も受け取った。一定の条件が満たされれば、Welichemは1500万CADの追加支払いを受け取る。
Stiefelのバーバラ・ホワイト上級副社長兼研究開発責任者は「WBI-1001を手に入れたことでStiefelの新しい皮膚科薬資産の臨床パイプラインを強化できるのはうれしい。わが社は皮膚病患者に強くコミットしており、この革新的な薬剤の開発を引き受けることに興奮している」と語っている。
▽WBI-1001について
WBI-1001は新しい非ステロイド系の局所使用抗炎症性の新化学品（NCE）で、軽度から中度の乾癬［i］、中度から重症のアトピー性皮膚炎［ii］向けの最大１２週間の単独療法の治療薬としての第I相、第II相臨床試験で効果と安全性を示した。
▽GSKグループ企業のStiefelについて
GSKグループ企業のStiefelは、ひとびとがより健康的な皮膚を実現するのを助けるため、世界中で皮膚科、皮膚科学を前進させることにコミットしている。革新への献身と医薬品、店頭渡し、美容皮膚科学製品への集中によってStiefelは皮膚健康業界の世界リーダーとしての地位を確立した。Stiefelについての詳しい情報はhttp://www.stiefel.comへ。
（参照）
[i] British Journal of Dermatology; 166(4):853-60
[ii] Journal of the European Academy of Dermatology and Venereology, Early View, Article first published online: 12 NOV 2011
ソース： Stiefel, a GSK company
▽問い合わせ先
GlaxoSmithKline Enquiries:
Media enquiries:
Kathleen Cuca,
+1-610-917-6914 (Philadelphia), or
Analyst/Investor enquiries:
Sally Ferguson,
+44(0)20-8047-5543 (London),
Tom Curry,
+1-215-751-5419 (Philadelphia),
Gary Davies,
+44(0)20-8047-5503 (London),
Jeff McLaughlin,
+1-215-751-7002 (Philadelphia), or
Ziba Shamsi,
+44(0)20-8047-3289 (London)
Stiefel, a GSK Company, Enters Agreement With Welichem Biotech, Inc. to Acquire a Novel Topical Agent for Psoriasis and Atopic Dermatitis
PR49507
RESEARCH TRIANGLE PARK, N.C., May 31, 2012 /PRN=KYODO JBN/ --
Stiefel, a GSK (NYSE:GSK) company, and Welichem Biotech, Inc. (WBI:CN),
have entered into an agreement for the acquisition by Stiefel of exclusive
development and commercialization rights to the novel anti-inflammatory agent,
WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.
WBI-1001 is currently in Phase II clinical development for the treatment of
psoriasis and atopic dermatitis. The transaction is subject to approval by
Welichem shareholders.
Welichem will receive an initial payment of CAD$35 million and is eligible
to receive additional milestone payments upon achievement of certain clinical
development milestones and upon commercialization in certain countries
following marketing approval from the corresponding regulatory agencies.
Under terms of the agreement, Stiefel has also received a conditional
right to acquire further exclusive rights to develop and commercialize WBI-1001
in China, Taiwan, Macao and Hong Kong, collectively. Upon satisfaction of
certain conditions, Welichem will receive an additional payment of
CAD$15million.
"I'm delighted to build upon Stiefel's clinical pipeline of novel
dermatology assets with the acquisition of WBI-1001," said Barbara White,
Senior Vice President and Head of Research and Development, Stiefel. "We have a
strong commitment to patients with skin conditions and are excited to undertake
development of this innovative agent."
About WBI-1001: WBI-1001 is a novel, non-steroidal, topical
anti-inflammatory new chemical entity (NCE) that has demonstrated efficacy and
safety in Ph1 and Ph2 clinical trials for the treatment of mild to moderate
psoriasis[i] and moderate to severe atopic dermatitis[ii] for up to 12 weeks as
a single therapy.
About Stiefel, a GSK company
Stiefel, a GSK company, is committed to advancing dermatology and skin
science around the world in order to help people better achieve healthier
skin. Stiefel's dedication to innovation, along with its focus on
pharmaceutical, over-the-counter and aesthetic dermatology products, has
established Stiefel as a world leader in the skin health industry. To learn
more about Stiefel, visit http://www.stiefel.com.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, Stiefel, a GSK company, cautions investors that any
forward-looking statements or projections made by Stiefel, a GSK company,
including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Factors that may affect Stiefel, a GSK company's operations are
described under 'Financial review & risk section" in GSK's Annual Report 2011
included as exhibit 15.2 to GSK's Annual Report on Form 20-F for 2011.
References:
[i] British Journal of Dermatology; 166(4):853-60
[ii] Journal of the European Academy of Dermatology and
Venereology,Early View, Article first published online: 12 NOV 2011
SOURCE: Stiefel, a GSK company
CONTACT: GlaxoSmithKline Enquiries:
Media enquiries:
Kathleen Cuca,
+1-610-917-6914 (Philadelphia), or
Analyst/Investor enquiries:
Sally Ferguson,
+44(0)20-8047-5543 (London),
Tom Curry,
+1-215-751-5419 (Philadelphia),
Gary Davies,
+44(0)20-8047-5503 (London),
Jeff McLaughlin,
+1-215-751-7002 (Philadelphia), or
Ziba Shamsi,
+44(0)20-8047-3289 (London)
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
